The World Trade Group Scientific Advisory Board is a group of recognised experts and practitionners from the life science industry.
The board meets a few times a year, either as a group or on a one-to-one basis to help drive the programmes to ensure it reflects the key industry concerns.
The board continually help review and mould our conference programmes, drawing upon their wealth of experience to advise on current industry developments and potential speakers, with many taking part in the event themselves.
Current Advisory Board Members Include:
|
|
Dr. Mario Maio
Head, Formulation & Process Development
Merck KGaA |
| Mario Maio is Formulation & Process Development Director at Merck-Serono, since 2007. At present, he is responsible for NCE drug product development, from early clinical investigation until transfer to commercial manufacturing. As well, he is responsible to implement and scale-up new drug delivery technologies that can be beneficial for products’ performance and patients’ convenience improvement. During his professional career, he has developed several oral and injectable formulations for Investigational Medicinal Products that are currently in Phase I-III clinical development. He studied at University of Turin, where he received a degree in Pharmacy and a degree in Pharmaceutical Chemistry and Technology. |
 |
Mark Wilson
Director, Collaboration Management, Europe
GSK |
| |
 |
Otmane Boussif
Head, Formulation Development – Biotech Products
Sanofi-Aventis |
| |
 |
Jay Lakshman
Technology Platform Leader and Project Leader, Pharmaceutical and Analytical Development
Novartis Pharma AG |
| |
 |
Barbara Lueckel
Global Drug Delivery Evaluator, Formulation Research/Pharma Partnering
F.Hoffmann-La Roche Ltd |
| Barbara Lueckel joined Roche as a Global Drug Delivery Evaluator in February 2007. She is responsible for identifying external drug delivery technology opportunities for both project-specific and strategic evaluations, leading feasibility studies as well as managing Roche’s strategic alliances with drug delivery partners. In that role, she is working with projects teams as well as technology area strategy teams to fulfill their drug delivery related needs. In addition, Barbara is also responsible for the delivery strategy of certain areas such as peptides.Barbara trained as a pharmacist and holds a PhD from the University of Basel. |
|
Clive Washington
Principal Scientist, Product Development
AstraZeneca |
| Clive Washington gained a PhD in Physical Chemistry from Sheffield University in 1981, and performed postdoctoral work in chemistry before being appointed as Lecturer in Pharmaceutics at Nottingham University. Subsequently he was promoted to Senior Lecturer before accepting a chair of Materials Chemistry at Salford University. In 2001 he left academia to join AstraZeneca as Principal Scientist in Product Development. His research interests include drug delivery, disperse and colloidal systems preparation and characterisation, surface-active and liquid crystal materials and the use of computational tools in pharmaceutical development. |
 |
Ursula Redeker
Global Head Technical Sciences
F. Hoffmann La-Roche |
Ursula graduated from University of Bonn with a diploma in Chemistry, received a Masters Degree from the University of California and a PhD in Organic Chemistry from University of Bonn in 1986. From 1986 to 1994 she worked with smaller Pharma respectively Biotech companies focusing on pharmaceutically active proteins. This included responsibilities in Research, Technical Development and Quality Control/Assurance of recombinant proteins and related drug products. In 1994 Ursula joined the Pharmaceutical & Analytical R&D department at Hoffmann La Roche , Basel, where she held various positions. |
 |
Dr. Makarand Jawadekar
Director, Portfolio Management & Analytics, Worldwide BioPharmaceutical Businesses
Pfizer |
Dr. Mak Jawadekar is currently a Director at Pfizer Inc. within Portfolio Management & Analytics Group, a part of Worldwide Bio Pharmaceutical Businesses in Groton-New London. In the recent past, he was responsible for Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies. He has extensive experience in creating and cultivating external partnerships and alliances for drug delivery technologies for Pfizer Global R & D. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics at the University of Minnesota. |
 |
Hanns-Christian Mahler
Ph.D. Head of Pharmaceutical & Device Development
F. Hoffmann-La Roche Ltd, Basel, Switzerland |
Since March 2010, Dr Mahler holds the position as Head of Pharmaceutical & Device Development being responsible for late-stage pharmaceutical, formulation and process development, Clinical Supplies (Phase 2 and 3), Production support of Biotech R&D projects, Primary Packaging and Device Development.
He joined Roche (Basel, Switzerland) in 2005 as Head of Formulation R&D Biologics in Technical Sciences (Pharma Research) .
From 2000-2005, he was working as Principal Scientist, Lab Manager and finally as CMC Team Leader for "Erbitux" at Merck KGaA (Darmstadt, Germany) .
Since 2003, he additionally holds a university teaching position for "Pharmaceutical Biotechnology" at the University of Frankfurt/Main, Germany.
Dr. Mahler obtained his “venia legendi” with the Habilitation in Pharmaceutical Technology at the University of Frankfurt in February 2010, holds a Ph.D. degree in Pharmacology & Toxicology obtained at the Johannes Gutenberg-University of Mainz, Germany, a degree in Pharmacy and specialization degrees in “Toxicology & Ecology” and “Pharmaceutical Sciences”.
|
Application for membership
We are continually seeking new members to join our advisory boards. If you would like more information or would like to help drive the conference programme by becoming an Advisory Board member, please contact: Gemma Fuller, Producer, Life Science Division, World Trade Group , T: +44 (0) 20 7202 7554
Please note acceptance onto the advisory board is not automatic and each enquiry will be judged on its own merit. The Advisory Board reserves the right to reject applications based on incomplete or unverifiable information.
|
